Clinical Trial

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with lupus nephritis (LN). It adopts a randomized, double-blind, placebo-controlled, multicenter trial design.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2025-11-28
Trial Details
NCT Number NCT07229742
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Active Lupus Nephritis
Enrollment 51 participants
Start Date 2025-11-22
Primary Completion 2027-06 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-01